BRD8518 is a PCSK9 inhibitor (EC50=0.23 μM). BRD8518 lowers blood lipids by upregulating LDLR expression and stimulating LDL uptake. BRD8518 can be used in the study of cardiovascular diseases[1].
References
[1] Xuhui Bao, et al. "Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside." Signal Transduction and Targeted Therapy 9.1 (2024): 13. DOI:10.1038/s41392-023-01690-3
